Background Cancer patients receiving chemotherapy have an increased risk of
cardiovascular complications. This limits the widespread use of lifesaving therapies, often …

Background Cardioprotective therapies represent an important avenue to reduce treatment-
limiting cardiotoxicities in patients receiving chemotherapy. However, the optimal duration …

Simple Summary Trastuzumab administered as a (neo) adjuvant therapy in radically treated
Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer patients …

Advances in cancer treatment have significantly improved the survival of patients with
cancer, but, unfortunately, many of these treatments also have long‐term complications …

We present a case of a young patient with breast cancer, whose oncological treatment
resulted in heart failure (HF) and who was successfully treated with modern cardioprotective …

Purpose: Cardiotoxicity is an important side effect of anthracycline. Cardioprotective drugs
for anthracycline remain inconclusive. We attempted to determine the role of angiotensin …

Background: Anthracyclines form the backbone of many systemic chemotherapy regimens
but are accompanied by dose-limiting cardiotoxicity. We elucidate the progression and …

Simple Summary Anthracyclines form the backbone of many systemic chemotherapy
regimens with great response rates for cancers. Yet, their established dose-limiting …

Background: Anthracyclines can improve survival in many types of malignancies, but dose-
dependent and irreversible results following the use of anthracyclines have been associated …

Purpose Cancer therapies including trastuzumab and anthracyclines are cardiotoxic and
cause cardiac dysfunction. To prevent cardiotoxicity, pharmacological agents used in heart …